| Name | Title | Contact Details |
|---|
Harvard Pilgrim Health Care is a full-service health benefits company serving more than one million members throughout Massachusetts, New Hampshire, Maine, Connecticut, and beyond. We`re dedicated to improving the quality and value of health care for the people and communities we serve. We recognize that health care is not one size fits all, and we`re working every day to create value for our members by respecting their unique values, languages, and cultures. For more than 40 years, we have built a reputation for exceptional clinical quality, preventive care, disease management, and member satisfaction, and have consistently been rated among the top plans in the country. In 2013 Harvard Pilgrim Health Care was ranked #1 private health plan in America for the 10th consecutive year. (#1 plan information available at http://countusin.harvardpilgrim.org/privacy) An independent, not-for-profit organization known for innovation that delivers better health and cost management, Harvard Pilgrim offers a wide variety of health insurance options for companies, families, and individuals. Our fully-insured and self-insured PPO, POS, and HMO plans are available with multiple variations tailored to the needs of our members and their employers. So, wherever, whenever you are looking for a partner in health benefits, or a great place to work, count us in. Harvard Pilgrim Health Care includes Harvard Pilgrim Health Care, Harvard Pilgrim Health Care of New England, and HPHC Insurance Company.
MedAccess is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
Parish Anesthesia Associates is a Metairie, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Berkeley Premium Nutraceuticals is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.